DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Fotemustine

Fotemustine

  • Bevacizumab Plus Fotemustine As First-Line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

    Bevacizumab Plus Fotemustine As First-Line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

  • Maintenance Therapy in Solid Tumors Marie-Anne Smit, MD, MS,1 and John L

    Maintenance Therapy in Solid Tumors Marie-Anne Smit, MD, MS,1 and John L

  • An Analysis of Toxicity and Response Outcomes from Dose

    An Analysis of Toxicity and Response Outcomes from Dose

  • Hyperthermic Isolated Hepatic Perfusion Using Melphalan for Patients with Ocular Melanoma Metastatic to Liver

    Hyperthermic Isolated Hepatic Perfusion Using Melphalan for Patients with Ocular Melanoma Metastatic to Liver

  • II. Recurring Tumors

    II. Recurring Tumors

  • Neoplasia Treatment Compositions Containing Antineoplastic Agent and Side-Effect Reducing Protective Agent

    Neoplasia Treatment Compositions Containing Antineoplastic Agent and Side-Effect Reducing Protective Agent

  • Other Alkylating Agents

    Other Alkylating Agents

  • Current Management of Conjunctival Melanoma Part 2: Treatment and Future Directions

    Current Management of Conjunctival Melanoma Part 2: Treatment and Future Directions

  • Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

    Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma

  • Summary of Product Characteristics

    Summary of Product Characteristics

  • Complete Response with Fotemustine and Bevacizumab After Early Progression Following Radiotherapy and Temozolomide Treatment in Patient with Glioblastoma Multiforme

    Complete Response with Fotemustine and Bevacizumab After Early Progression Following Radiotherapy and Temozolomide Treatment in Patient with Glioblastoma Multiforme

  • EANO Guidelines on the Diagnosis and Treatment of Diffuse Gliomas of Adulthood

    EANO Guidelines on the Diagnosis and Treatment of Diffuse Gliomas of Adulthood

  • Sorafenib Plus Daily Low-Dose Temozolomide for Relapsed Glioblastoma: a Phase II Study

    Sorafenib Plus Daily Low-Dose Temozolomide for Relapsed Glioblastoma: a Phase II Study

  • GUIDE MANAGEMENT of HIGH GRADE GLIOMA Principles Of

    GUIDE MANAGEMENT of HIGH GRADE GLIOMA Principles Of

  • 1078-0432.CCR-10-2363.Full-Text.Pdf

    1078-0432.CCR-10-2363.Full-Text.Pdf

  • Chemotherapy Drugs

    Chemotherapy Drugs

  • Liste Des Molécules

    Liste Des Molécules

  • Neoplasia Treatment Compositions Containing Antineoplastic Agent and Side-Effect Reducing Protective Agent

    Neoplasia Treatment Compositions Containing Antineoplastic Agent and Side-Effect Reducing Protective Agent

Top View
  • Bioflo Port Chemotherapy Testing Tech Note
  • Nber Working Paper Series the Impact of New Drug
  • Treatment of Metastatic Uveal Melanoma: Systematic Review
  • Unusual Serpentine Supravenous Hyperpigmentation During Chemotherapy Treatment
  • SFPO and ESOP Recommendations for The
  • EMETOGENICITY of CHEMOTHERAPY REGIMENS Version 2019
  • Antiemetic Regimens
  • DTIC), BCNU (Carmustine), Cisplatin and Tamoxifen (DBPT
  • FEAM) As a New Conditioning Regimen for Lymphoma Patients Undergoing Auto-SCT: a Multicenter Feasibility Study
  • Cytostatics in the Aquatic Environment: Analysis, Occurrence, and Possibilities for Removal
  • Monthly Literature Update October 2018
  • Fotemustine: a Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas
  • BRAIN CANCER TREATMENT REGIMENS (Part 1 of 9) Clinical Trials: the NCCN Recommends Cancer Patient Participation in Clinical Trials As the Gold Standard for Treatment
  • PDF Hosted at the Radboud Repository of the Radboud University Nijmegen
  • Australian PI – Tradename (Active Ingredient)
  • Chemotherapy Drugs
  • Viability of Microorganisms in Novel Chemical and Biopharmaceutical Anticancer Drug Solutions
  • Vitamin C): a New Frontier in the Treatment of Intraocular Cancer


© 2024 Docslib.org    Feedback